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AMPK Modulation Ameliorates Dominant Disease Phenotypes of CTRP5 Variant
in Retinal Degeneration
Abstract
Late-onset retinal degeneration (L-ORD) is an autosomal dominant disorder caused by a missense
substitution in CTRP5. Distinctive clinical features include sub-retinal pigment epithelium (RPE) deposits,
choroidal neovascularization, and RPE atrophy. In induced pluripotent stem cells-derived RPE from L-ORD
patients (L-ORD-iRPE), we show that the dominant pathogenic CTRP5 variant leads to reduced CTRP5
secretion. In silico modeling suggests lower binding of mutant CTRP5 to adiponectin receptor 1
(ADIPOR1). Downstream of ADIPOR1 sustained activation of AMPK renders it insensitive to changes in
AMP/ATP ratio resulting in defective lipid metabolism, reduced Neuroprotectin D1(NPD1) secretion, lower
mitochondrial respiration, and reduced ATP production. These metabolic defects result in accumulation
of sub-RPE deposits and leave L-ORD-iRPE susceptible to dedifferentiation. Gene augmentation of L-ORDiRPE with WT CTRP5 or modulation of AMPK, by metformin, re-sensitize L-ORD-iRPE to changes in cellular
energy status alleviating the disease cellular phenotypes. Our data suggests a mechanism for the
dominant behavior of CTRP5 mutation and provides potential treatment strategies for L-ORD patients. ©
2021, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright
protection may apply.
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AMPK modulation ameliorates dominant disease
phenotypes of CTRP5 variant in retinal
degeneration
Kiyoharu J. Miyagishima 1,10, Ruchi Sharma2,10, Malika Nimmagadda2,10, Katharina Clore-Gronenborn2,
Zoya Qureshy2, Davide Ortolan 2, Devika Bose2, Mitra Farnoodian2, Congxiao Zhang1, Andrew Fausey2,
Yuri V. Sergeev3, Mones Abu-Asab4, Bokkyoo Jun5, Khanh V. Do5, Marie-Audrey Kautzman Guerin5,
Jorgelina Calandria5, Aman George3, Bin Guan6, Qin Wan1, Rachel C. Sharp 7, Catherine Cukras8,
Paul A. Sieving 9, Robert B. Hufnagel6, Nicolas G. Bazan 5, Kathleen Boesze-Battaglia7, Sheldon Miller1 &
Kapil Bharti 2 ✉

Late-onset retinal degeneration (L-ORD) is an autosomal dominant disorder caused by a
missense substitution in CTRP5. Distinctive clinical features include sub-retinal pigment
epithelium (RPE) deposits, choroidal neovascularization, and RPE atrophy. In induced pluripotent stem cells-derived RPE from L-ORD patients (L-ORD-iRPE), we show that the
dominant pathogenic CTRP5 variant leads to reduced CTRP5 secretion. In silico modeling
suggests lower binding of mutant CTRP5 to adiponectin receptor 1 (ADIPOR1). Downstream
of ADIPOR1 sustained activation of AMPK renders it insensitive to changes in AMP/ATP
ratio resulting in defective lipid metabolism, reduced Neuroprotectin D1(NPD1) secretion,
lower mitochondrial respiration, and reduced ATP production. These metabolic defects result
in accumulation of sub-RPE deposits and leave L-ORD-iRPE susceptible to dedifferentiation.
Gene augmentation of L-ORD-iRPE with WT CTRP5 or modulation of AMPK, by metformin,
re-sensitize L-ORD-iRPE to changes in cellular energy status alleviating the disease cellular
phenotypes. Our data suggests a mechanism for the dominant behavior of CTRP5 mutation
and provides potential treatment strategies for L-ORD patients.
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L

ate-onset retinal degeneration (L-ORD) is a rare, genetically
dominant monogenic retinal dystrophy that is characterized
by atrophic or neovascular pathology of the retinal pigment
epithelium (RPE)1. RPE is a monolayer of polarized, pigmented
cells at the back of the eye that plays a critical role in maintaining
the homeostasis of the subretinal space and adjacent photoreceptor cells necessary for vision2. L-ORD-induced retinal
changes are minimal until after 40 years of age3. Initial evidence
of disease includes the presence of reticular pseudodrusen and
thinning of the choroid, and later in life, progresses to advanced
stages characterized by increased sub-RPE deposits, extrafoveal
RPE atrophy, and choroidal neovascularization4,5. Thus, we
hypothesized that an analysis of L-ORD-retinal pigment epithelium derived from a family with the p.Ser163Arg mutation could
provide insight into the cellular mechanisms underlying its
pathogenesis6.
L-ORD is caused by amino acid substitutions (e.g., p.Ser163Arg) in the CTRP5 protein, encoded by the C1QTNF5 gene, a
bicistronic mRNA partner of membrane frizzled-related protein
(MFRP)7. The C1q/TNF-related protein (CTRP) family are
paralogues to ADIPONECTINS8, and both protein families are
widely studied for their roles in regulating energy homeostasis
and fatty acid metabolism in non-eye tissues8,9. Like ADIPONECTIN, all CTRP members possess four distinct structural
domains: (1) N-terminal signal peptide that targets the protein for
secretion; (2) variable region; (3) collagen region; and (4) a
C-terminal globular domain10. All CTRPs form bouquet-like
trimeric structures, and some family members, including CTRP5,
can assemble into homologous or heterologous higher-order
multimeric complexes10–12. Adiponectin proteins affect cellular
metabolism through adiponectin receptors 1 (ADIPOR1) and
ADIPOR213,14. Recent publications suggest that a member of the
CTRP family of proteins, CTRP9, also acts as a ligand for ADIPOR1 and ADIPOR215,16. ADIPOR1 primarily regulates gluconeogenesis and fatty acid oxidation, whereas ADIPOR2 is mainly
involved in oxidative stress and inﬂammation17.
Previously, mutant CTRP5 was shown to form heterooligomers
with wild-type CTRP511,18,19, but the mechanism for genetically
dominant behavior of CTRP5 mutations is still not clear. CTRP5
protein has been identiﬁed as a putative biomarker for obesity
and chronic obstructive pulmonary disease20, suggesting a role
for this protein in regulating cellular fatty acid metabolism. The 5′
AMP-activated protein kinase (AMPK) has been suggested as an
intracellular mediator of CTRP5 to regulate fatty acid metabolism
and energy homeostasis21. RPE cells participate in diurnal phagocytosis of photoreceptor outer segments (POS) which have an
abundance of fatty acids and lipids22,23. Increasing evidence
suggests that RPE cells metabolize fatty acids from POS membranes and recycle metabolic substrates to photoreceptors

through ketogenesis. RPE also secrete docosahexaenoic acid
(DHA)-derived neuroprotective factors like Neuroprotectin D1
(NPD1) that protects the photoreceptors from photooxidative
stress and, in a cell-autonomous fashion, the RPE itself23–26.
AMPK has been suggested as a key regulator of POS digestion in
the RPE27. It has been suggested that dysregulation of fatty acid
and lipid metabolism contributes to the formation of sub-RPE
deposits in AMD28.
In the present study, we demonstrated that L-ORD RPE
derived from patient induced pluripotent stem cells (L-ORDiRPE) accurately recapitulate the human disease phenotype: elevated sub-RPE deposition of APOE - a demonstrated component
of drusen, and mispolarized secretion of vascular endothelial
growth factor (VEGF) - a causative factor of CNV. Mechanistically, reduced secretion of CTRP5 and predicted lower binding
afﬁnity of mutant CTRP5 to ADIPOR1 receptor is the likely
reason for the genetically dominant behavior of this disease. We
show that lower CTRP5 levels are associated with constitutively
activated AMPK leading to its insensitivity to changes in the
cellular energy status. Using a gene therapy approach, overexpression of WT CTRP5 in patient cells overcomes lower
CTRP5 levels and rescue mispolarized VEGF secretion. Metformin, an anti-diabetic drug, rescued L-ORD-iRPE metabolic dysfunction by resensitizing AMPK to changes in cellular stress,
restoring energy homeostasis, and ameliorating disease cellular
phenotypes.
Results
Induced pluripotent stem cells (iPSCs) were derived from ﬁbroblasts isolated from skin biopsies of four siblings—two had a
clinical and molecular diagnosis of L-ORD due to the recurrent
p.Ser163Arg variant, and the other two were unaffected and did
not carry the pathogenic variant7. All iPSC lines expressed
pluripotency markers: OCT4, NANOG, SOX2, and SSEA4 and
were karyotypically normal (Table 1 and Fig. S1). An in vitro
embryoid body assay demonstrated similar capabilities between
all iPSC clones to differentiate into cell types from all three germ
layers (Table 1). iRPE derived from two iPSC clones per donor
were used for further experiments. Thus, each experiment presented here uses averaged data from iRPE derived from four iPSC
clones of two unaffected siblings (healthy-iRPE) and four iPSC
clones of two patients (L-ORD-iRPE).
L-ORD pathophysiology replicated in patient-derived iRPE
cells. C1QTNF5 (NM_001278431.2) exon 2 was Sanger sequenced
in iPSCs to verify that only the patient cells retained the S163R
L-ORD mutation (Fig. 1a). All eight iPSC clones were differentiated into RPE cells and matured on transwells for 6 weeks to

Table 1 Validation of pluripotency, presence of pathogenic C1QTNF5 variant, karyotyping was performed on iPSCs in the study.
Identity (short tandem repeat) analysis was performed on iRPE and iPSCs to ensure no cross contamination.
Donor derived cells

iPSC line clone

Pluripotency markers

Germ-layer
markers

Normal
karyotype

Sanger
sequencing

Short tandem repeat

Healthy-iRPE Donor 1
Healthy-iRPE Donor 1
Healthy-iRPE Donor 2
Healthy-iRPE Donor 2
L-ORD-iRPE Donor 1
L-ORD-iRPE Donor 1
L-ORD-iRPE Donor 2
L-ORD-iRPE Donor 2

LORCF1-Clone1
LORCF1-Clone2
LORCF2-Clone1
LORCF2-Clone2
LORPF1-Clone1
LORPF1-Clone2
LORPF2-Clone1
LORPF2-Clone2

✓
✓
✓
✓
✓
✓
✓
✓

✓
✓
✓
✓
✓
✓
✓
✓

✓
✓
✓
✓
✓
✓
✓
✓

✓
✓
✓
✓
✓
✓
✓
✓

✓
✓
✓
✓
✓
✓
✓
✓

Miyagishima et al. investigate the pathological mechanisms underlying mutant CTRP5 function in late-onset retinal degeneration (L-ORD). With human iPSC-derived RPE cells, they demonstrate that in
L-ORD-iRPE, constitutive activation of AMPK disrupts cellular metabolism/energy homeostasis, changes apical/basal VEGF secretion, and metformin treatment corrects these associated phenotypes.
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Fig. 1 L-ORD-iRPE replicates disease cellular phenotype in a dish. a Sanger sequencing conﬁrms the presence of p.Ser163Arg variant in L-ORD-iPSCs.
The heterozygous single nucleotide variant in C1QTNF5 (c.489 C > C/G) appears as a peak within a peak. b Boxplots of ΔCt values for RPE signature genes
are comparable in healthy and L-ORD-iRPE (boxplots represent n = 3 independent experiments from at least two donors; 25th, median, and 75th
percentiles correspond to the bottom, middle, and top of each box). c TEM images of healthy and L-ORD-iRPE monolayers show polarized RPE structure
including abundant apical processes (orange arrow), melanosomes (magenta arrow), and basally located nuclei (white arrow). Scale bar: 2 µm. d SEM
images of healthy-iRPE and L-ORD-iRPE demonstrate hexagonal morphology and abundant apical processes. Scale bar: 2 µm. e Boxplot of cell area reveals
larger cell size in L-ORD-iRPE than heathy-iRPE. iRPE monolayers were immunostained with membrane marker (ADIPOR1) to outline their hexagonal shape
(healthy-iRPE: n = 9; L-ORD-iRPE: n = 6). Total of n > 10,000 cells counted. f Scatterplot of dedifferentiation-related genes shows no difference in L-ORDiRPE (n = 2 donors) compared to healthy-iRPE (n = 2 donors). g Transepithelial resistance (TER) measurements were performed using an epithelial
voltohmmeter in L-ORD-iRPE (n = 264 inclusive of all clones, two donors) compared to healthy-iRPE (n = 266 inclusive of all clones, 2 donors). (h)
Comparative analysis of sub-RPE APOE (red)-positive deposits (n = 25) in healthy-iRPE (n = 11) and L-ORD-iRPE (n = 14) show 1.3-fold (p = 0.01) increase
in APOE staining. Hoechst 33342 staining conﬁrms the lack of cellular debris contributing towards APOE staining. Scale bar: 100 µm. i Apical and basal
VEGF secretion is mispolarized in L-ORD-iRPE (white, n = 13) compared with healthy-iRPE (gray, n = 17). For validation of iPSC-derived lines and
karyotyping analysis: See Table 1 and Fig. S1. ∗p < 0.05; ∗∗∗p < 0.001; ns not signiﬁcant.

form physiologically relevant epithelial monolayers using our
previously published protocol29. L-ORD and healthy-iRPE
monolayers expressed similar levels of developmental (MITF,
PAX6, DCT, TYRP1, TYR, GPNMB) and mature RPE markers
(RLBP1, ALDH1A3, BEST1, RPE65, CLDN19, EZRIN, MFRP)29
(Fig. 1b and Supplementary Fig. 2a), suggesting the ability of LORD-associated cells to mature and acquire RPE cell-speciﬁc
transcriptional proﬁle. Transmission electron microscopy (TEM)
of iRPE monolayers revealed typical polarized RPE features like
abundant apical processes (orange arrow), apically located melanosomes (magenta arrow), and basally located nuclei (white
arrow) in all eight iRPE samples (Fig. 1c). Scanning electron
microscopy (SEM) also conﬁrmed abundant apical processes in
both healthy and L-ORD-iRPE but suggested increased cell size of
L-ORD-iRPE cells as compared to healthy-iRPE (Fig. 1d and
Supplementary Fig. 2b). To further conﬁrm this observation,
iRPE monolayers stained for cell borders were analyzed to assess

differences in cell size. Cell area was 35% larger and more variable
in L-ORD-iRPE compared to healthy-iRPE (average cell area
±SD: 106.9 ± 68.0 µm2 for L-ORD-iRPE and 79.2 ± 37.2 µm2 for
healthy-iRPE; p < 0.001) (Fig. 1e). Similar spatial irregularities
have been reported in RPE cells of AMD donor eyes and are often
associated with RPE cell dedifferentiation30. However, no signiﬁcant difference in the expression of 84 dedifferentiation genes
was seen in L-ORD-iRPE as compared to healthy-iRPE (Fig. 1f
and Supplementary Table 1). Transepithelial resistance (TER)
measurements conﬁrmed the formation of functional tight
junctions between neighboring RPE cells and showed a signiﬁcant
increase in L-ORD-iRPE compared to healthy-iRPE (mean ±
SEM, TER: 931.3 ± 15.6 Ω•cm2 for L-ORD-iRPE, and
602.6 ± 15.6 Ω•cm2 for healthy-iRPE; Fig. 1g, p < 0.001). Sub-RPE
deposits are a characteristic feature of L-ORD, which shares
some similarities to the lipid-containing deposits seen in AMD
eyes31. Apolipoprotein E (APOE), associated with high-density
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lipoproteins (HDLs), is a well-known marker for sub-RPE
deposits32. About 1.3-fold higher subcellular APOE-positive
deposits were observed in L-ORD-iRPE as compared to
healthy-iRPE (Fig. 1h and Supplementary Fig. 2c, p < 0.01).
Despite normal epithelial monolayer formation, L-ORD-iRPE
exhibited mispolarized vascular endothelial growth factor (VEGF)
secretion (Fig. 1i). In particular, the basal VEGF secretion was
reduced by 63% (p < 0.05) in L-ORD-iRPE compared to healthyiRPE perhaps contributing to the thinning of the choroid
observed clinically in L-ORD patients. These results suggest that
the iRPE recapitulated L-ORD phenotypes associated with the
most common disease-causing variant in CTRP5.
Reduced CTRP5 secretion and lower binding of mutant
CTRP5 with adiponectin receptor 1. Since C1QTNF5 and MFRP
share a bicistronic transcript, we investigated whether the L-ORD
p.Ser163Arg variant altered the expression of either transcript.
qRT-PCR revealed comparable ΔCt values for C1QTNF5 and

MFRP transcripts across all samples, indicating no patientspeciﬁc differences in mRNA expression (p = 0.8 and 0.5 for
CTRP5 and MFRP, respectively, Supplementary Fig. 3a). ELISAbased quantitative analysis showed L-ORD-iRPE CTRP5 apical
and basal secretion was signiﬁcantly lower compared to the
healthy-iRPE (Ap: 14.3-fold, p < 0.001; Ba: 19.7-fold, p < 0.001, LORD-iRPE vs healthy) in agreement with previously reported
ﬁndings19,33 (Fig. 2a, b). These results suggested that mutant
CTRP5 protein might be trapped inside L-ORD-iRPE. To
determine if mutant CTRP5 traps the WT version inside the cell
we used lentivirus technology to overexpress V5-tagged mutant
and FLAG-tagged WT CTRP5 proteins in healthy-iRPE cells
(Fig. 2c, Supplementary Fig. 3b). At a multiplicity of infection
(MOI) of 0.5, expression of mutant and WT CTRP5 was barely
detectable inside the cell. When the MOI of the mutant protein
was increased to 3.0 while keeping the WT MOI constant at 0.5,
signiﬁcantly higher levels of WT CTRP5 could be detected inside
the cell (Fig. 2c, compare green signal between the top and

Fig. 2 Expression and localization of CTRP5 in L-ORD-iRPE. a, b Apical and basal CTRP5 secretion measured by ELISA in the culture medium are both
signiﬁcantly decreased (n = 14). c Coexpression of V5-tagged WT CTRP5 (green) and FLAG-tagged S163R CTRP5 (red) in healthy-iRPE. V5-tagged WT
CTRP5 expressing lentivirus construct was transduced at MOI 0.5 for both top and bottom panels. MOI of Flag-tagged S163R CTRP5 expressing lentivirus
construct was 0.5 for cells in the top panel and 3.0 for cells in the bottom panel. Scale bar: 10 µm d Confocal microscopy images of untreated and
baﬁlomycin (BafA1) treated (3 h) healthy-iRPE and L-ORD-iRPE co-stained with CTRP5 (red) and ATG5 (green). (n = 3 images per condition). Scale bar:
10 µm. e Representative confocal microscopy images showing colocalization of CTRP5 (red) with membrane receptors ADIPOR1 (green, upper panel) and
no colocalization with ADIPOR2 (green, lower panel). Nuclear stain (blue). Scale bar: 5 µm. f TEM image of immunogold labeled ADIPOR1 (6 nm gold
particle) and CTRP5 (12 nm gold particle) demonstrate the co-binding of two proteins (arrow). Scale bar: 500 nm. g Western blot detects CTRP5 in the
membrane fraction of iRPE cells immunoprecipitated using anti-ADIPOR1 antibodies and not in lanes immunoprecipitated with the IgG antibody or with
only beads. h Probabilistic model of the interaction of integral membrane protein ADIPOR1 (blue) and CTRP5 (teal) determined using published
crystallographic structures and reﬁned by molecular dynamics. i The polar serine to arginine substitution on CTRP5 (blue) is predicted to have an
electrostatic repulsive interaction with neighboring arginine residue, Arg122, on ADIPOR1 (magenta) reducing the likelihood of interaction. See also Fig. S4.
∗∗∗p < 0.001.
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bottom panels). Whereas overexpression of WT CTRP5 alone at
an MOI of 3.0 did not cause similar accumulation inside the cell
(Supplementary Fig. 3b). This suggests that the mutant protein
traps the WT version inside the cell in heterooligomers and
reduces its secretion (Fig. 2c). These results provide evidence that
the CTRP5 pathogenic variant affects the secretion of the native
wild-type protein as well.
To determine where the mutant CTRP5 is trapped inside the
cell, we checked its co-localization with different intracellular
organelles. Previously it was suggested that mutant CTRP5
overexpressed in HEK293 cells colocalizes with the endoplasmic
reticulum19. In both healthy and L-ORD-iRPE, we noted similar
colocalization of CTRP5 with the endoplasmic reticulum (ER)
marker, CALRETICULIN, suggesting that the mutant CTRP5 is
not trapped in the ER [Supplementary Fig. 3c; Pearson’s
correlation coefﬁcient between CTRP5 (red) and CALRETICULIN (green): healthy-iRPE 0.37 ± 0.06; L-ORD-iRPE 0.26 ± 0.05.
p = ns]. Consistently, mRNA expression of ER-stress markers did
not appear to be elevated in L-ORD-iRPE, suggesting no ER stress
in L-ORD-iRPE (Supplementary Fig. 3d). Similarly, no signiﬁcant
difference in colocalization was noted between healthy and LORD-iRPE for early endosomal marker EEA134 [Supplementary
Fig. 3e; Pearson’s correlation coefﬁcient between CTRP5 (green)
and EEEA1 (red): healthy-iRPE 0.21 ± 0.03; L-ORD-iRPE
0.22 ± 0.02. p = ns]. Rather, it appears that in L-ORD-iRPE,
CTRP5 was targeted for lysosomal degradation (Supplementary
Fig. 3f and Fig. 2d). Baﬁlomycin A1 (BafA1) treatment, which
prevented lysosomal acidiﬁcation35 enhanced CTRP5 (red)
accumulation, more so in L-ORD-iRPE as compared to healthyiRPE (compare untreated samples with BafA1 treated samples —
Supplementary Fig. S3f and Fig. 2d). Furthermore, strong
colocalization was seen between CTRP5 and LAMP1 (green,
lysosomal marker; Supplementary Fig. 3f) and CTRP5 and ATG5
(green, autophagosome marker; Fig. 2d). Pearson’s correlation
coefﬁcient showed between 2–2.5-fold higher colocalization
between CTRP5 and ATG5 in L-ORD-iRPE as compared to
healthy-iRPE (Fig. 2d; untreated: healthy-iRPE 0.07 ± 0.02; LORD-iRPE 0.16 ± 0.04. p < 0.05; baﬁlomycin A1 treated: healthyiRPE 0.16 ± 0.02; L-ORD-iRPE 0.37 ± 0.08. p < 0.01). No localization for mutant was seen in the sub-RPE space (Supplementary
Fig. 3g). Overall, these results suggest that in L-ORD-iRPE, the
mutant CTRP5 variant along with WT CTRP5 are degraded via
the lysosomal-autophagy pathway resulting in reduced secretion.
To discover intracellular signaling pathways affected by mutant
CTRP5, we looked for its potential partner receptors on the RPE
cell surface. Since the globular domain of CTRP5 is ~40%
homologous to ADIPONECTIN36, we sought to determine if it
interacts with the adiponectin receptor family13. Consistent with
the dominant apical secretion of CTRP5, ADIPOR1, and
ADIPOR2 receptors are predominantly present on the apical
surface of healthy and L-ORD-iRPE cells (Supplementary Fig. 4a,
b). Interestingly, ADIPOR1 mRNA (Supplementary Fig. 4c,
p < 0.05) and protein (Supplementary Fig. 4d, e, p < 0.05)
expression were found to be approximately twofold higher in
healthy-iRPE compared to L-ORD-iRPE. High-resolution immunoﬂuorescence microscopy in healthy-iRPE revealed speciﬁc colabeling of CTRP5 (red-ligand) with Adiponectin receptor 1
(ADIPOR1, green-receptor), and not with Adiponectin receptor 2
(ADIPOR2, green) (Fig. 2e). Native immunogold labeling of
healthy-iRPE further conﬁrmed CTRP5 (12 nm gold particle) and
ADIPOR1 (6 nm gold particle) interaction, as indicated by black
arrows (Fig. 2f). These co-labeling experiments suggest that
apically secreted CTRP5 interacts with ADIPOR1 on the RPE
surface and may modulate its activity. Co-IP revealed a direct
interaction between ADIPOR1 and CTRP5 (Fig. 2g) further
validating microscopy ﬁndings.
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To further support that native CTPR5 interacts with
ADIPOR1, we modeled in silico interactions using existing
structural models for both proteins11,18,37. Figure 2h shows a
simpliﬁed representation of the heterocomplex of two structures
reﬁned in water, demonstrating that a CTRP5 trimer can be
docked to the binding domain of ADIPOR1 positioned in a lipid
membrane (Fig. 2h and Supplementary Methods) and may
compete with ADIPOR1 ligand ADIPONECTIN for the receptor’s binding cavity. Tu and Palczewski previously showed that
the pathogenic p.Ser163Arg substitution alters the charge at the
top of the trimeric head of CTRP518. Consistent with those
observations, simulation of CTRP5 binding to ADIPOR1 reveals
that the Arg163 residue lies on the interface of CTRP5 expected
to dock with ADIPOR1 and predicts amino acid residues that are
most likely to show interaction (Fig. 2i). The serine to arginine
change in CTRP5 adds a positive charge that repels the Arg122
on ADIPOR1’s surface, increasing their Cα-Cα distance by 87.5%
(native: ~4.8 Å; mutant: 9.0 Å). Similar changes are predicted for
other recently reported disease-associated CTRP5 variants
(p.Gly216Cys, p.Prp188Thr) that are also close to its surface
and are expected to repel ADIPOR1, reducing the likelihood of
interaction compared to the WT protein (Supplementary Fig. 4f,
g). Overall, these results suggest that the mutant protein not only
reduces the secretion of the WT counterpart but it likely also
reduces its binding afﬁnity to the ADIPOR1 receptor.
CTRP5 ﬁne-tunes AMPK sensitivity to cellular energy status.
Adiponectin and its receptors regulate lipid metabolism in an
AMP-activated protein kinase (AMPK) dependent mechanism,
and the activation of ADIPOR1 stimulates ceramidase activity
promoting cell survival38. Reduced ADIPOR1 activity leads to the
accumulation of ceramides and their metabolic derivatives, which
have been linked to macular degeneration39. Compared to healthy-iRPE, L-ORD-iRPE did not show excessive ceramide accumulation or altered ceramidase activity (Supplementary Fig. 5a,
b), suggesting that lower binding of mutant CTRP5 to ADIPOR1
leads to its constitutive activation rather than inhibition of
ADIPOR1 ceramidase activity. Therefore, the following experiments sought to determine whether ADIPOR1 downstream signaling, including the AMPK pathway, was constitutively active in
L-ORD-iRPE.
Consistent with constitutively active ADIPOR1 in L-ORDiRPE, at baseline, in serum-containing media, the levels of
phospho (T172)-AMPK (pAMPK), a measure of AMPK activity,
was ~20% higher in L-ORD-iRPE compared to healthy-iRPE
(121 ± 7.5% vs. 100 ± 4%; Fig. 3a, p < 0.01). Since CTRP5 and
ADIPOR1’s natural ligand, ADIPONECTIN, are known to
circulate at high concentrations in the serum36, we hypothesized
that serum-free media would uncover the effect of exogenous
CTRP5 on ADIPOR1. Thus, iRPE were incubated with
recombinant CTRP5 globular form (0.2 µg/mL gCTRP5) for
30 min in the presence (+) and absence (−) of serum to evaluate
its role in AMPK signaling (Fig. 3b). Based on this notion, the
addition of gCTRP5 to healthy or L-ORD-iRPE in serumcontaining media did not alter AMPK activity (1.1 ± 0.09 – LORD-iRPE; 1.0 ± 0.01 – healthy-iRPE, Fig. 3b, p = ns), but in
serum-deprived media, the addition of gCTRP5 led to a 20%
decrease in pAMPK levels in healthy-iRPE. In contrast, this
decrease was not seen in L-ORD-iRPE (1.0 ± 0.1 – L-ORD-iRPE,
p = ns; 0.8 ± 0.04 – healthy-iRPE, p < 0.01; Fig. 3b). To better
elucidate the ADIPOR1-CTRP5 (receptor-ligand) interaction, we
performed a ligand dose-response curve (in serum-free media) by
adding increasing concentrations of recombinant full-length
CTRP5 (Fig. 3c). In healthy-iRPE, increasing the concentration
of exogenous CTRP5 resulted in a dose-dependent reduction in
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Fig. 3 Reduced antagonism of CTRP5 on ADIPOR1 results in altered AMPK signaling in L-ORD-iRPE. a pAMPK levels determined by ELISA in L-ORDiRPE (n = 15; 120.6% ± 0.08) compared to healthy-iRPE (n = 21; 100% ± 0.04), cultured in 5% serum-containing media. b Effect of recombinant globular
CTRP5 (0.2 µg/mL) on pAMPK levels in the presence (+) or absence (−) of serum in healthy-iRPE (81% ± 4, n = 9) and L-ORD-iRPE (99% ± 1, n = 6),
measured by ELISA. Data were normalized to the untreated condition (0 µg/mL gCTRP5), considered as 100%. c Effects of recombinant full-length CTRP5
(0.2, 2, and 25 µg/mL) on pAMPK levels in healthy-iRPE (n = 6) and L-ORD-iRPE (n = 6) incubated in serum-free medium for 5 h, measured by ELISA.
d Effect of increasing cytosolic AMP with AICAR (an AMP analog, 2 mM) treatment or decreasing ATP with BAM15 (a mitochondrial uncoupler, 500 nM)
on AMPK activity in healthy-iRPE and L-ORD-iRPE. All data were normalized to the 0% serum-containing untreated condition (AICAR: n = 20 for healthyiRPE, n = 16 for L-ORD-iRPE; BAM15: n = 8 for healthy-iRPE, and n = 6 for L-ORD-iRPE). e Representative Western blot of PGC1α expression in healthy and
L-ORD-iRPE. f Quantiﬁcation of Western blots for PGC1α. Healthy-iRPE (n = 4). L-ORD-iRPE (n = 4). g Representative Western blot for phospho (S570)PGC1α in L-ORD-iRPE compared to healthy-iRPE. h Quantiﬁcation of Western blots for phosphor (S570)-PGC1 α in healthy-iRPE (n = 4) and L-ORD-iRPE
(n = 4). i APOE expression (red) in untreated and adenine 9-beta-d-arabinofuranoside (1 µM, ara-A) treated L-ORD-iRPE. Collagen IV (green) marks RPE
basal surface and nuclei (blue) are labeled with Hoechst 33342. (n = 3 images each) Scale bar: 10 µm. j ELISA detection of apical and basal VEGF secretion
in untreated and adenine 9-beta-d-arabinofuranoside (1 µM, ara-A) treated L-ORD-iRPE (n = 6). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns not signiﬁcant, AU
arbitrary units.

pAMPK levels at (50% reduction at 25 µg/mL, p < 0.05). But in LORD-iRPE, the addition of CTRP5 did not affect AMPK activity,
suggesting that the mutant CTRP5 has a dominant effect on the
inhibitory activity of WT CTRP5 on ADIPOR1. Taken together,
these data suggest that in healthy-iRPE cells, CTRP5 helps meet
RPE energy demands by providing metabolic regulation to ﬁnetune ADIPOR1-dependent AMPK activity and this regulation is
lacking in patient cells.
AMPK is a sensitive indicator of the cell energy status and is
canonically activated by increased AMP:ATP ratio40. Therefore, we
further characterized the AMPK activity (in serum-free media) of
healthy and L-ORD-iRPE under conditions (increased AMP:ATP
ratio) known to stimulate AMPK phosphorylation41,42. iRPE were
incubated in serum-deprived media for 5 h to reduce intracellular
ATP levels36 followed by 30 min exposure to AICAR (an AMP
6

analog) or BAM15 (a mitochondrial uncoupler that reduces ATP
production) to further minimize the ATP cytoplasmic pool.
Consistent with the data in Fig. 3a–c, increased cytoplasmic
AMP (AICAR) or decreased ATP (BAM15) appropriately activated
AMPK in healthy-iRPE, but not in L-ORD-iRPE (Fig. 3d, p < 0.001
and p < 0.05 for AICAR and BAM15, respectively). Taken together,
these ﬁndings suggest that constitutively active ADIPOR1 in LORD-iRPE leads to chronic AMPK activation causing a failure in
these cells to sense the AMP:ATP ratio making modulators of
AMPK a potential target for therapeutic intervention.
Since AMPK binds to and activates PGC1α by direct
phosphorylation we investigated whether L-ORD-iRPE exhibited
changes in expression of PGC1α or its phospho-form. Although
the levels of PGC1α were unchanged in L-ORD-iRPE compared
to healthy (Fig. 3e, f, p = ns), the levels of phospho-PGC1α at Ser-

COMMUNICATIONS BIOLOGY | (2021)4:1360 | https://doi.org/10.1038/s42003-021-02872-x | www.nature.com/commsbio

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02872-x

570 that is known to inhibit its transcriptional activity43 were
increased 3.5-fold (p < 0.05) in L-ORD-iRPE compared to
healthy-iRPE (Fig. 3g, h, p < 0.05), consistent with constitutively
active AMPK and suppressed PGC1α activity in these cells.
To determine if constitutively active AMPK was indeed
responsible for pathological features seen in L-ORD-iRPE, we
subjected L-ORD-iRPE to adenine 9-beta-d-arabinofuranoside
(1 µM, ara-A), a potent AMPK activity inhibitor44. Inhibition of
AMPK activity in POS-fed (1 week) L-ORD-iRPE lessened subRPE APOE deposits, a key hallmark of L-ORD (Fig. 3i).
Furthermore, AMPK inhibition led to a ~50% reduction in
apical (Ap: 0.9 ± 0.2 ng/mL, p < 0.05) and basal (Ba: 0.3 ± 0.04 ng/
mL, p < 0.001) VEGF secretion compared to untreated L-ORDiRPE (Ap: 1.5 ± 0.2 ng/mL; Ba: 0.7 ± 0.07 ng/mL respectively,
Fig. 3j). Taken together, these data suggest that the pathogenic
CTRP5 variant leads to pathological symptoms in L-ORD-iRPE
cells likely due to constitutively activated AMPK signaling, thus
incapacitating its ability to sense changes in cytosolic
AMP:ATP ratio.
Constitutively active AMPK disrupts PEDF-R mediated
synthesis of retinal neuroprotectants and mitochondrial
respiration in L-ORD-iRPE. To determine the molecular
mechanism driven by constitutively active AMPK pathology in LORD-iRPE cells, we examined the expression of its downstream
signaling pathways. Pigment epithelium-derived factor (PEDF)
and its receptor PEDF-R are particularly important targets of
activated AMPK45 because of their principal roles in regulating
lipid metabolism and the release of free fatty acids. The expression (Fig. 4a) and apical localization (Fig. 4b) of PEDF-R (red) in
L-ORD and healthy-iRPE were comparable, but we found a 50%
reduction in apical/basal ratio of PEDF secretion in L-ORD-iRPE
(L-ORD-iRPE: 5.5 ± 1.1; healthy-iRPE: 13.2 ± 3.4; Fig. 4c,
p < 0.05). PEDF binding to PEDF-R stimulates the enzymatic
phospholipase A2 activity of PEDF-R46. Accordingly, we
observed a 44% reduction in phospholipase A2 activity of PEDFR in L-ORD-iRPE (L-ORD-iRPE: 56.1% ± 7.1; healthy-IRPE:
100% ± 16.9; Fig. 4d, p < 0.05), consistent with the observed
reduced apical secretion of PEDF.
To conﬁrm that reduced phospholipase A2 activity was indeed
associated with activated AMPK, we serum-starved healthy-iRPE
cells to increase the levels of pAMPK. Following 24 h of serum
starvation, phospholipase A2 activity was decreased by ~30%,
suggesting that elevated pAMPK levels in L-ORD-iRPE are
responsible for reduced phospholipase A2 activity in these cells
(control: 100 ± 10%; serum-starved: 72 ± 7%; Fig. 4e, p < 0.05).
Phospholipase A2 activity is required for mitochondrial function
and the breakdown of phospholipids from phagocytosed POS
into biologically active compounds such as DHA, eicosanoids,
and Neuroprotectin D1 (NPD1)26. Reduced phospholipase A2
activity in L-ORD-iRPE resulted in 2.5-fold lower mitochondrial
basal respiration rates (L-ORD-iRPE: 69.1 ± 4.6 pmol/min;
healthy-iRPE: 171.1 ± 7.0 pmol/min; p < 0.05) and threefold lower
ATP production (21.4 ± 2.2 pmol/min) compared to healthyiRPE (58.7 ± 16.1 pmol/min, p < 0.05) (Fig. 4f, g). In addition, the
NPD1 production was ~10-fold lower in L-ORD-iRPE
(1.1 ± 0.4 pg) compared to healthy-iRPE (10.8 ± 0.8 pg; Fig. 4h).
We found that L-ORD-iRPE phagocytose higher amounts of
POS, as conﬁrmed by a ﬂow cytometry-based phagocytosis assay
where ~50% more POS uptake was observed (Fig. 4i, p < 0.01).
This likely occurred as a compensatory mechanism to offset lower
NPD1 production by increasing the available free DHA poolsize26. But despite increased POS uptake, reduced phospholipase
A2 activity suggested that L-ORD-iRPE have a lower ability to
digest POS47. In agreement with this interpretation, the levels of
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docosahexaenoic acid (DHA), a substrate from which very longchain polyunsaturated fatty acids are derived, were found to be
~25% lower in apical media from L-ORD patient iRPE fed
photoreceptor outer segments (POS) (n = 12 transwells per
clone × 5 days; Supplementary Fig. 5c). Collectively, these results
suggest that chronically active AMPK-perturbed PEDF/PEDF-R
activity triggering pathological changes in L-ORD-iRPE via
altered lipid metabolism, reduced ability to digest POS, reduced
secretion of cytoprotective compounds needed by photoreceptors,
and lowered mitochondrial respiration.
Recently, gene augmentation was shown to rescue disease
phenotype in patient iPSC-derived RPE cells for a dominant
maculopathy caused by mutations in gene BEST148. We asked if a
similar gene therapy approach was feasible for L-ORD-iRPE.
Patient cells were transduced with progressively higher amounts
of lentivirus constructs expressing GFP and WT CTRP5. GFP
ﬂuorescence conﬁrmed increased expression both with increasing
MOI and duration after transduction (Supplementary Fig. 6a, b).
With increasing MOI of the WT CTRP5 expressing construct,
6–7x higher expression of CTRP5 on the apical side and 3–4x
higher expression on the basal side of cells could be detected
[Supplementary Fig. 6c, d; MOI 1.5: Ap (p < 0.01), Ba (p < 0.001);
MOI 3.0: Ap (p < 0.001), Ba (p < 0.05]. Consistent with increased
secretion of CTRP5, pAMPK levels were reduced ~23% in LORD-iRPE with increasing concentration of WT CTRP5
(Supplementary Fig. 6e; MOI 0.5 and 1.5: p = ns; MOI 3.0:
p < 0.05). Again, consistent with the increased CTRP5 secretion
and reduced pAMPK levels, mispolarized VEGF secretion was
also corrected in WT CTRP5 overexpressed L-ORD-iRPE
[Supplementary Fig. 6f; MOI 1.5: Ap (p < 0.01), Ba (p < 0.001);
MOI 3.0: Ap (p < 0.001), Ba (p < 0.05)]. Together this data further
reinforces our hypothesis that the dominant behavior of S163R
mutation is through decreased secretion of CTRP5 in RPE cells
and suggests that gene augmentation provides a potential
treatment option for L-ORD patients.
Metformin corrects L-ORD pathological phenotype. To further
determine if defective POS digestion and lipid metabolism contribute to the pathological features in L-ORD-iRPE cells, both
healthy- and L-ORD-iRPE were fed photoreceptor outer segments (POS) for 7 consecutive days. POS-fed L-ORD-iRPE
exhibited increased and variable cell size (mean area ± SD:
135.4 ± 55.0 µm2), when compared to healthy-iRPE (95.8 ±
44.0 µm2, p < 0.001), perimeter, major axis, and minor axis
(Figs. 5a, b, 1e and Supplementary Fig. 7a–c) or when compared
to unfed L-ORD-iRPE cells (106.9 ± 68.0 µm2, p < 0.001) (Fig. 1e
and Supplementary Fig. 7a). POS feeding for 7 days also increased
the expression of dedifferentiation-related genes in L-ORD-iRPE
(Fig. 5c). Compared to healthy-iRPE, L-ORD-iRPE upregulated
53/84 genes (>4-fold) associated with dedifferentiation (e.g.,
ESR1, PDGFRB, TMEFF1, KRT14, PTK2, SOX10, GSK3B,
TSPAN13, WNT5a, GNG11, ITGAV, SNAI3, and MMP9) following 1 week of daily POS feeding, suggesting a possible
mechanism of RPE atrophy and L-ORD disease phenotype
worsening due to life-long POS uptake by diseased patient
RPE cells.
Metformin, an anti-diabetic drug49, has been used in the past
for its lipid-lowering effects and for reversing epithelial
dedifferentiation50. We asked whether metformin treatment of
L-ORD-iRPE could reverse some of the pathophysiology induced
by POS feeding. L-ORD and healthy-iRPE were treated daily with
POS and 3 mM metformin for 1 week. Notably, metformin
treatment of L-ORD-iRPE mitigated the POS-induced increase in
cell size (Area: L-ORD untreated: 135.4 µm2 ± 55 vs. L-ORD
metformin: 117.9 µm2 ± 34.1, p < 0.0001, compare Fig. 5b to d, 5e,
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and Supplementary Fig. 8a). Additional cell morphometry
metrics like perimeter, major axis, and minor axis of cells were
also decreased upon metformin treatment of L-ORD-iRPE
(Supplementary Fig. 8b–d). Metformin treatment (magenta) also
downregulated the expression of 31 dedifferentiation genes by
threefold or more (e.g., ESR1, PDGFRB, TMEFF1, KRT14, PTK2,
SOX10, GSK3B, and TSPAN13) including 21/53 that were
8

overexpressed fourfold under POS feeding conditions (compare
Fig. 5c, f, p < 0.01–p < 0.001).
Metabolic reprograming is proposed to play a critical role in
RPE dedifferentiation51. To determine if metformin was able to
restore fatty acid oxidative capacity through ketone body
generation, we compared β-HB and NPD1 released apically in
the presence of metformin. As seen in Fig. 5g, h, metformin
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Fig. 4 Altered lipid metabolism in L-ORD-iRPE contributes to reduced neuroprotective signaling. a, b PEDF-R (red) immunolabeling in healthy-iRPE and
L-ORD-iRPE. Cell nuclei (blue) and the actin cytoskeleton (phalloidin, green). Healthy-iRPE (n = 8), L-ORD-iRPE (n = 6). Scale bar: 10 µm. c Apical/basal
ratio of PEDF secretion in L-ORD-iRPE (n = 11) as compared to healthy-iRPE (n = 12), measured by ELISA. d Phospholipase A2 activity in L-ORD-iRPE
(n = 6) and healthy-iRPE (n = 5), measured by ELISA. e Phospholipase A2 activity of healthy-iRPE under basal and serum-starved (24 h) cell culture
conditions (n = 6). f Seahorse assay results demonstrating oxygen consumption rate (OCR) in healthy (n = 18) and L-ORD-iRPE (n = 18) before and after
the addition of mitochondrial respiration inhibitors (oligomycin, FCCP, antimycin A/rotenone). g ATP production measured from the Seahorse experiment
in L-ORD-iRPE (21.4 ± 2.2 pmol/min, n = 18) compared to healthy-iRPE (58.7 ± 16.1 pmol/min, n = 18). h Apically secreted Neuroprotectin D1 (NPD1)
measured by tandem mass spectrometry lipidomic analysis in POS-fed (4 h) L-ORD-iRPE (n = 12) and healthy-iRPE (n = 12). i Flow cytometry-based
analysis of photoreceptor outer segment phagocytosis in L-ORD-iRPE and healthy-iRPE (n = 14). ∗p < 0.05, ∗∗p < 0.01.

addition increased β-HB and NPD1 release in L-ORD-iRPE
(p < 0.01). This increased β-HB synthesis coincided with
increased levels of HMGCS2, the enzyme catalyzing the
committed step in ketone body generation, PEDF-R, and
PRKAG1 an AMPK subunit (Supplementary Fig. 9a).
We then asked if metformin could rescue L-ORD-iRPE
pathological phenotypes like sub-RPE APOE deposits and
mispolarized VEGF secretion. Consistent with reduced phospholipase A2 activity and altered lipid metabolism in L-ORD-iRPE, a
week of POS feeding exaggerated the sub-RPE APOE deposition.
In images of POS-fed healthy-iRPE, APOE was found to be
primarily on the apical side of cells as shown by their disparate
integrated density values on the apical (yellow arrow) and basal
(white arrow) sides (Fig. 6a —healthy-iRPE: top panel—low
magniﬁcation and bottom panel—high magniﬁcation; quantiﬁcation in Fig. 6e − 8.45 ± 3.09 a.u.). In contrast, POS-fed L-ORDiRPE (Fig. 6b—L-ORD-iRPE: top panel—low magniﬁcation and
bottom panel—high magniﬁcation) exhibited increased levels of
APOE in the sub-RPE space (quantiﬁcation in Fig. 6e;
46.38 ± 2.51 a.u.). The white arrow in Fig. 6b indicates a basal
increase in APOE deposits in pores of the transwell membrane
reported previously for cultured RPE cells with AMD
phenotype52. Metformin treatment of L-ORD-iRPE ameliorated
the accumulation of APOE-containing basal deposits (Fig. 6c—LORD-iRPE plus metformin: top panel—low magniﬁcation and
bottom panel—high magniﬁcation; quantiﬁcation in Fig. 6e;
13.6 ± 4.6 a.u., p < 0.001), but it didn’t affect the overall APOE
levels as conﬁrmed by Western blot analysis (Fig. 6d).
Furthermore, metformin treatment corrected mispolarized
VEGF secretion L-ORD-iRPE (compare Figs. 1i and 6f, LORD-iRPE, n = 13, Ap: 3.2 ± 0.5 ng/mL, Ba: 2.2 ± 0.3 ng/mL;
metformin-treated L-ORD-iRPE, n = 10, Ap:2.1 ± 0.4 ng/mL, Ba:
4.8 ± 1.2 ng/mL; Ap: p = 0.1; Ba: p < 0.05; healthy-iRPE, n = 17,
Ap:2.5 ± 0.4 ng/mL, Ba: 3.6 ± 0.6 ng/mL). Notably, the average
VEGF Ba/Ap ratio calculated from individual transwells from LORD-iRPE (0.9 ± 0.1) was signiﬁcantly improved with metformin
(3.2 ± 0.9, p < 0.01) consistent with Ba/Ap ratios observed in
healthy-iRPE (1.8 ± 0.2, Fig. 1i). Figure 5g, h conﬁrmed that
metformin worked in L-ORD cells via improving mitochondrial
activity as shown previously53. To check if this improvement also
reset the AMPK activity in a feedback loop from mitochondria,
we assessed the activity of the AMPK and its ability to sense
cellular energy status deﬁned by the AMP:ATP ratio. L-ORDiRPE treated with metformin resulted in an increased ability of
AMPK to respond to AICAR stimulation compared to L-ORDiRPE not treated with metformin (Fig. 6g compare with Fig. 3d).
This result suggests that metformin relieved chronic activation of
AMPK and restored normal energy homeostasis. Taken together,
these data indicate that L-ORD-iRPE are susceptible to lipidstress induced dedifferentiation and that metformin can reactivate mitochondrial activity, reduce lipid stress, and resensitize
AMPK, likely in a feedback loop. All together these changes in
cellular metabolism alleviate pathological dedifferentiation of
cells through downregulating dedifferentiation gene expression,

reducing sub-RPE APOE deposition, and correcting mispolarized
VEGF secretion.
Discussion
The monogenic dominant origin and pathological features of
L-ORD have provided the basis for developing a patient-speciﬁc
in vitro model improving our understanding of RPE pathogenesis
that leads to vision loss in patients. Here, we reproduced three
well-documented L-ORD disease cellular phenotypes—sub-RPE
deposits, mispolarized VEGF secretion, and RPE atrophy6 in
patient RPE cells in vitro and provided direct evidence of the
dominant-negative effect of the mutant CTRP5 protein. In
human iPSC-derived RPE cells, we test the hypothesis that
CTRP5 curtails ADIPOR1-driven AMPK signaling, which acts as
a metabolic sensor to help control energy homeostasis, resistance
to stress, and aging54. More speciﬁcally, chronic AMPK stimulation causes an imbalance in its ability to sense changes in
intracellular AMP:ATP ratio, leading to diminished fatty acid
utilization and oxidative phosphorylation, mispolarized VEGF
secretion, the formation of sub-RPE deposits, and RPE atrophy.
Our analysis provides a molecular link between observations of
sub-RPE deposits, RPE atrophy, and the pathogenic CTRP5
variant that effectuates AMPK to become constitutively active
resulting in diminished PEDF signaling in L-ORD-iRPE cells.
Reduced phospholipase A2 activity of the PEDF receptor is
known to reduce the efﬁciency of fatty acid metabolism, oxidative
phosphorylation, and POS digestion25,55. This was conﬁrmed in
L-ORD-iRPE cells, which after a week of POS feeding exhibited
decreased NPD1 and DHA secretion. Reduced phospholipase A2
activity and reduced PGC1α activity lower the ability of the
mitochondria to generate ATP using oxidative phosphorylation.
It has been reported that lower oxidative phosphorylation in RPE
cells leads to increased glycolytic rate, which has been linked to
cellular dedifferentiation in the RPE, as seen in our L-ORD
cells56,57. Metabolic defects induced RPE dedifferentiation has
been shown previously leading to photoreceptor degeneration in
a mouse model58. Overall, our work provides a basis for understanding how the L-ORD-associated CTRP5 variant disrupts lipid
metabolism and DHA availability and leads to RPE atrophy
and photoreceptor degeneration clinically observed in L-ORD
patients.
The recycling of DHA through the intercellular matrix is a
tightly regulated process involving interphotoreceptor retinoidbinding protein (IRBP)59 that also trafﬁcs retinoids in the
extracellular space between photoreceptors and the RPE. A
similar dual role for ADIPOR1 has also been reported. In addition to stimulating AMPK activity, it also regulates DHA uptake
in photoreceptors and the RPE17. Although DHA is enriched in
photoreceptors and has long been shown to be integral for
photoreceptor outer segment renewal60, DHA is now appreciated
as a precursor for many bioactive lipids, such as NPD1, that are
important for maintaining the functional integrity of the
photoreceptors26,61.
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Fig. 5 Metformin counteracts the increased susceptibility to dedifferentiation in L-ORD-iRPE. a, b Representative immunoﬂuorescent images of the
membrane marker ZO-1 (green) in healthy (a) and L-ORD-iRPE (b) following 7 consecutive days of POS uptake. Scale bar 20 µm. c The effect of POS uptake
on the expression of dedifferentiation-related genes in L-ORD-iRPE compared to healthy-iRPE. A dashed line indicates a fourfold difference. Housekeeping
genes: ACTB and GAPDH. d Concurrent treatment of L-ORD-iRPE with metformin (3 mM) on POS-induced increase in cell size (ZO-1, green) after 7 days of
POS uptake. Scale bar 20 µm. e Quantiﬁcation of cell area after 7 days of POS uptake and metformin (3 mM) treatment in L-ORD-iRPE. Cells were labeled with
anti-ZO-1 antibody and area was quantiﬁed using an AI-based algorithm80, low whisker: 5% of data, low hinge: 25% of data, midline: median, high hinge: 75%
of data, high whisker: 95% of data. (n = 6 images). f Expression of 31 dedifferentiation-related genes in metformin-treated (magenta) L-ORD-iRPE (fed POS for
7 days) compared to untreated cells. A dashed line indicates a fourfold difference. Housekeeping genes: ACTB and GAPDH. g Apically secreted betahydroxybutyrate (β-HB) in L-ORD-iRPE after 1 week of metformin treatment. Cells were supplied with a β-HB metabolic substrate, BSA-palmitate conjugate, for
3 h before measuring β-HB levels (n = 12). h Secreted NPD1 in untreated (n = 8) and metformin-treated L-ORD-iRPE (n = 9) measured by tandem mass
spectrometry lipidomic analysis. Cells were POS-fed for 24 h prior to media collection. ∗p < 0.05, **p < 0.01, ∗∗∗p < 0.001.

The highest expression of CTRP5 protein is noted in the eye
and adipose tissue9,10. To date, most work on the role of CTRP5
and the adiponectin pathway has been based on clinical or
in vitro studies performed in non-eye tissues62,63. In myocytes,
CTRP5 was shown to regulate the phosphorylation of AMPK,
thereby regulating fatty acid oxidation in an autocrine manner36.
Because of the structural homology between ADIPONECTIN and
the CTRP family of proteins, ADIPOR1 has been proposed as a
receptor for the CTRP family of proteins as well16. Consistently,
our in silico modeling demonstrated that CTRP5 trimers could
10

interact with the known ADIPONECTIN docking site on ADIPOR1. Furthermore, in RPE cells a strong co-labeling of CTRP5,
speciﬁcally with ADIPOR1 and not ADIPOR2, was observed.
Consistent with the immunolabeling data Co-IP conﬁrmed
physical interaction between ADIPOR1 and CTRP5. Our results
support direct interaction between the two proteins—similar to
CTRP9’s interaction with ADIPOR1 in the brain64.
Our data suggest that reduced secretion of CTRP5 is likely
because oligomers of wildtype and mutant protein are trapped
inside the cell. An increase in expression of the FLAG-tagged
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Fig. 6 Metformin ameliorates L-ORD cellular phenotypes. a–c Immunoﬂuorescent images of cryosectioned healthy (a) and L-ORD-iRPE [without
metformin (b), with metformin (c)] monolayers fed POS for 7 consecutive days and stained for APOE (red), COLLAGEN IV (COLIV, green), nuclei with
Hoechst 33342 (blue). Top panels (a–c) show 20x magniﬁcation images, scale bar: 50 µm. Representative 60x magniﬁcation images are shown in bottom
panels (a–c), scale bar: 10 µm. Apical APOE is indicated with yellow arrows and basal with white arrows (n = 4) d Representative Western blot and
quantiﬁcation of APOE signal in healthy (n = 4) and L-ORD-iRPE without (n = 3) and with metformin treatment (n = 3). e Quantiﬁcation of APOE signal
from images shown in panels a–c. (n = 4 for healthy-iRPE; n = 5 for L-ORD-iRPE; n = 4 for L-ORD-iRPE with metformin). f ELISA-based measurements of
apical and basal VEGF secretion in metformin-treated healthy and L-ORD-iRPE (n = 10; Ap: 2.07 ± 0.4; Ba: 4.8 ± 1). g pAMPK levels in response to AICAR
(2 mM) in L-ORD-iRPE (n = 6) treated with metformin, measured by ELISA.

mutant CTRP5 increased the intracellular signal for V5-tagged
WT CTRP5 in a dose-dependent manner suggesting the mutant
variant traps the WT inside the cell and lowers its secretion. The
heterooligomers of WT-mutant CTRP5 are likely trapped in an
endo-lysosomal compartment inside the cell and likely targeted
for lysosomal degradation. Pearson’s correlation coefﬁcient
clearly showed the strongest co-labeling of CTRP5 with LAMP1/2
and ATG5, especially when lysosomal degradation was blocked
using baﬁlomycin A1. Our results differ from Shu et al. that
showed endoplasmic reticulum localization of WT and mutant
CTRP519. This discrepancy is likely because Shu et al. used an
overexpression system of either WT or mutant CTRP5. A similar
discrepancy exists between our data and another study looking at
overexpression of p.Ser163Arg CTRP5 in a mouse model65.
Dinculescu observed large, round intracellular globular aggregates

of CTRP5 in this model65, which are not seen in our L-ORDiRPE. We are detecting endogenous expression of heterooligomers of WT CTRP5 as opposed to overexpression of WT or
mutant proteins that was done in an RPE cell line or an adult
mouse RPE.
All three reported variants (p.Gly216Cys, p.Pro188Thr, and
p.Ser163Arg) of the CTRP5 globular domain are located on the
inter-subunit interface with ADIPOR1. Consistently, our in silico
modeling implies that all three pathogenic variants decrease the
protein stability (>8 kJ/mol) and reduce the likelihood that the
WT/mutant CTRP5 heterooligomers would interact with its
receptor, ADIPOR1. Based on our data, we suggest that the
dominant nature of L-ORD-associated variants is due to a combination of these two phenomena: (1) that heterooligomers of
mutant and WT CTRP5 proteins are retained within the RPE;
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and, (2) that there is a reduced afﬁnity between secreted mutant/
WT CTRP5 oligomers and ADIPOR1. Here we suggest that in
healthy-RPE, native CTRP5 acts as an inhibitor for ADIPOR1
receptors since apical supplementation of gCTRP5 resulted in
reduced pAMPK activity (Fig. 3b). In L-ORD, reduced availability
of mutant/WT CTRP5 and reduced binding afﬁnity of mutant/
WT CTRP5 multimers leads to chronic activation of ADIPOR1.
These results are further conﬁrmed by the signiﬁcantly higher
constitutive AMPK phosphorylation seen in L-ORD-iRPE cells
and by the absent effect on ADIPOR1 ceramidase activity (Supplementary Fig. 4c, d). The use of a gene augmentation approach
to overexpress WT CTRP5 in L-ORD-iRPE rescued disease
phenotypes—it increased the secretion of CTRP5, reduced
pAMPK levels, and corrected mispolarized VEGF secretion. This
data further supports our results that entrapment of the WTvariant by the mutant variant inside the cell is the likely reason
for the dominant disease phenotype and it provides a gene
therapy approach to treat L-ORD patients.
Taken together, this evidence suggests a role for CTRP5ADIPOR1 interactions in mediating the disease phenotype in
L-ORD patient cells. The loss of CTRP5 inhibitory actions on
ADIPOR1 signaling results in constitutively active AMPK—a
master regulator of lipid metabolism. This is a critical outcome
for RPE, since it ingests a high-fat diet of photoreceptor outer
segments on a daily basis66. Similar to our ﬁndings, AMPK
inhibition of PEDF expression has been reported in adipocytes
and hepatocytes67. PEDF is known to prevent intracellular calcium overload in rd1 mouse photoreceptors by acting upon
plasma membrane Ca2+ ATPase pumps68. Additionally, it suppresses RPE dedifferentiation and migration and improves RPE
mitochondrial function69. In L-ORD-iRPE, chronic AMPK activation reduces PEDF expression—thereby signiﬁcantly reducing
the phospholipase activity associated with PEDF-R, which is
required to mobilize free fatty acids from digested POS.
Metformin is a widely prescribed drug for treating type 2
diabetes and acts by lowering blood glucose among patients by
reducing hepatic glucose production, but its mechanisms of
action are broad70. It’s been proposed that metformin may
indirectly inﬂuence AMPK activity via improvement in mitochondrial oxidative phosphorylation, fatty acid oxidation, protein
translation, or by altering AMPK binding/interaction with
LKB171–74. Through improved ATP production via mitochondria, metformin likely reduces cellular dependency on glycolysis75
and reverses RPE dedifferentiation50. The same phenomenon was
observed in metformin-treated L-ORD-iRPE cells. Importantly,
metformin has also been shown to delay retinal degeneration in
RD10 mice and to protect the RPE from sodium iodate-induced
damage76. Of notable interest in L-ORD-iRPE is the increased
expression of: (1) PEDF-R, which stimulates the release of free
fatty acids; (2) HMGCS2, which catalyzes ketogenesis—converting excess products of fatty acid oxidation (acetyl-CoA) to βhydroxybutyrate, a metabolic substrate utilized by the retina23;
and (3) PRKAG1, the AMP/ATP binding subunit of AMPK
which has been shown to inﬂuence the degree of AMPK stimulation. Combined, these three effects of metformin remodel lipid
metabolism in the RPE, improve fatty acid utilization and alter
APOE distribution thus reducing sub-RPE lipid deposition.
Implications of clinical and in vitro data. The RPE is situated
between the neurosensory retina and the vascular choroid and
serves as a metabolic gatekeeper achieving homeostasis by balancing the energy demands of the retina while maintaining the
integrity of the blood–retina-barrier. Interestingly, under normal
circumstances, the dominant secretion of VEGF by the RPE is
basal toward the choroid77. In L-ORD however, the underlying
12

inherited metabolic defect alters this secretion proﬁle and is
reversed—favoring secretion toward the distal retina. This
reversal is corrected by treatment with metformin and VEGF can
return to protecting the choroid. Hence future investigations are
needed to further evaluate the pathophysiological aspects of this
relationship.
Metformin and other AMPK regulators are in clinical use78.
Thus, the connection with altered AMPK activity provides a
potential treatment opportunity for L-ORD and for other retinal
degenerative diseases. Our in vitro data indicates that the diseaseassociated phenotypes of L-ORD were strongly inﬂuenced by
early intervention/pretreatment with metformin. As is the case in
other epithelia where epidemiological evidence suggests that
metabolic imbalance contributes to disease onset and/or progression in diabetes and cancer79, the therapeutic mechanism of
metformin is likely through a shift in the metabolic state toward
the norm and prevention of dedifferentiation. Overall, our study
provides novel insights into the role of CTRP5 in the RPE, how
the pathogenic variant in L-ORD causes dominant disease, and
provides further evidence that metformin can be a beneﬁcial
intervention for the treatment of L-ORD.
Methods

Human iPSC generation using patient-derived ﬁbroblast cells. Written
approvals for human skin-tissue collection and iPSC generation were obtained as
part of an NEI IRB-approved protocol, 11-E1-0245. Written informed consent was
received from participants prior to inclusion in the study. The skin biopsy samples
were “coded” where no personally identiﬁable information (PII) was directly
available to the researchers. Human biospecimens were stored according to the
Guidelines for human biospecimen storage, tracking, sharing, and disposal within
the NIH Intramural Research Program.
Skin punch biopsies were obtained from a clinically and genotypically
conﬁrmed family of L-ORD patients (one female age 57, one male age 51) and
unaffected siblings (two males ages 58 and 54) (NIH Clinical Center) with their
signed consent. Affected members of this family were diagnosed with late-onset
retinal degeneration contributing to symptomatic night blindness and progressive
loss of peripheral vision. Affected individuals had clinical molecular genetic testing
conﬁrming that they carry the familial p.Ser163Arg missense variant in CTRP5.
(See Supplementary Methods for iPSC generation, validation, and differentiation
into iRPE).

Study design. In this study, we generated iPSC-RPE from patients with late-onset
retinal degeneration (L-ORD) and their unaffected (“healthy”) siblings to use as an
in vitro model to investigate L-ORD pathogenesis. By including multiple donors
from the same family (~50% of the genome shared) and generating multiple iPSC
clones from each donor we mitigated the likelihood that phenotypic differences
could be attributed to differences in genetic background. Additionally, the cellular
sources for all the iPSCs were the same: skin ﬁbroblasts and all iPSCs were derived
using a non-integrating approach (Sendai virus). The passage numbers and time in
culture were comparable across the entire study. iPSC-RPE were seeded onto
transwells at 250k/well and matured for >6 weeks before being used for the following assays to determine the underlying disease mechanism and to consequently
design a method to rescue the disease phenotype in vitro. Speciﬁcally, we investigated how the single missense mutation in CTRP5 affects its expression, secretion,
and its interaction with other proteins. We identiﬁed ADIPOR1 as a likely candidate for interaction and conﬁrmed this by co-immunoprecipitation. Since
L-ORD is a dominant monogenic disorder, it was presumed that the effect of the
mutation would be highly penetrant which was conﬁrmed by the signiﬁcant
reduction in CTRP5 secretion in all L-ORD iPSC-RPE. Thus, the downstream
effects of this phenotypic change (i.e., AMPK activity) outweighed any confounding factors that may be present in this model. All subsequent experiments
and assays are described in detail below and in the Supplementary Methods.
RNA extraction and cDNA synthesis. iRPE on transwells were washed 3x with
DPBS. RNA was extracted using NucleoSpin RNA (Macherey-Nagel, Düren,
Germany, #740955.50) per manufacturer’s instructions. Brieﬂy, cells were lysed by
placing them in RA1 Lysis buffer 350 µL + 3.5 µL β-mercaptoethanol/well (Thermo
Fisher Scientiﬁc, #21985023) for 10–15 min prior to pipetting the cell lysate and
immediately ﬂash freezing with liquid nitrogen. Elution of RNA was performed,
and cDNA was prepared from mRNA using SuperScript III First-Strand Synthesis
kit (Thermo Fisher Scientiﬁc, #11904-018). cDNA was diluted to 1 ng/µl.
qPCR. Using validated primer sets (BioRad Laboratories, Inc., Hercules, CA) we
ordered a custom-designed 96 gene PrimePCR four-quadrant, 384 well plates for
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(1) human AMPK and fatty acid metabolism (Biorad, #10025214), and a 384 well
plate for human genes related to (2) epithelial-to-mesenchymal transition (EMT)
(Biorad, #10034487). Quantitative polymerase chain reaction (qPCR) was run in
duplicate or triplicate using RT2 SYBR Green qPCR Mastermix (Qiagen, Hilden,
Germany, #330503) on a ViiA 7 Real-Time PCR System (Thermo Fisher Scientiﬁc,
#4453536). Housekeeping gene (HPRT and TBP) transcript levels were used as
internal controls. Genes with non-detect Ct values in both unaffected siblings and
L-ORD patients were removed from the analysis. Relative quantiﬁcation was calculated using the 2−ΔΔCT method. For qPCR primer analysis of individual genes of
interest (CTRP5, MFRP)/housekeeping gene (RPL13A) primers were ordered from
Integrated DNA Technologies (Coralville, IA). The following primers and primer
sequences were used.
CTRP5. FWD: GCAAGTTCACCTGCCAGGTGCC
REV: GGATTCGCCATTCTTCACCAGATC
MFRP. FWD: TCACCAACTGCTCTGCACCTGG
REV: AGTCAAACTTGCACTCGTCCTGAG
Transmission electron microscopy. Samples for TEM were processed as previously described (Ogilvy et al., 2014). Brieﬂy, iRPE were washed 3x in PBS and
then ﬁxed in PBS-buffered glutaraldehyde (2.5% at pH 7.4) (VWR, Randor, PA,
#102092-014) and treated with 0.5% ice-cold PBS-buffered osmium tetroxide
(Electron Microscope Sciences, #19190) and embedded in epoxy resin. Ultrathin
sections (~90 nm thick) were cut on an ultramicrotome and mounted on 200hexamesh copper grids (Electron Microscopy Sciences, #G200H-Cu). TEM images
were acquired on a JEOL JEM-1010 transmission electron microscope (JEOL,
Peabody, MA).
Scanning electron microscopy. iRPE on transwells were ﬁxed overnight in 2.5%
glutaraldehyde + 1% formaldehyde in 0.1 M sodium cacodylate buffered solution.
Samples were cut to ﬁt the sample holder and underwent ethanol dehydration
progressing sequentially through ddH20 (5 min), 30% ethanol (10 min), 50%
ethanol (10 min), 70% ethanol (20 min), 90% ethanol (5 min), 95% ethanol (5 min),
100% ethanol (5 min), 100% ethanol (5 min), 100% ethanol (5–20 min) (Sigma,
#459844500 ML) while transported to a critical point drying (CPD) machine
(Leica, Wetzlar, Germany, #EM CPD300) where they were further dehydrated.
Samples were then mounted onto SEM pin stub mounts (Ted Pella, Redding, CA,
#16111-9) and coated with 10–15 nm of gold using a low vacuum sputter coater
(Leica, #EM ACE 200) and stored in a desiccator until imaged on a Zeiss EVO MA
10 scanning electron microscope (SEM).
Transepithelial electrical resistance (TER). Resistance measurements were taken
using the STX2 electrode set with the EVOM2 meter (World Precision Instruments, Sarasota, FL). The unit area resistance was calculated by multiplying the
measured resistance by the effective membrane area (1.12 cm2).
Immunostaining of iRPE monolayers. iRPE monolayers were ﬁxed in 4% PFA
(Electron Microscopy Sciences, #15710) for 10 min, washed 3x in PBST (1x PBS,
0.5% Tween20), and permeabilized in ICC blocking buffer (1x PBS, 1% BSA, 0.25%
Tween20, 0.25% Triton X-100) for 1 h. iRPE were incubated overnight at room
temperature with antibodies diluted in ICC blocking buffer at the following dilutions: CTRP5 (1:100, Bioss, #bs-11717R), MFRP (1:100, R&D Systems, #AF1915),
APOE (1:100, EMD Millipore, #AB947), Collagen IV (1:100, EMD Millipore,
#ab756p), Ceramide (1:100, Enzo, #ALX-804-196-T050), ADIPOR1 (1:300, Enzo,
#ALX-210-645-C200), ADIPOR2 (1:250, EMD Millipore, #MABS1166), EZRIN
(1:200, Sigma, #E8897), ZO-1/TJP1 (1:100, LS-Bio, #LS-B9774), EEA1 (1:100,
Abcam, #ab70521), (1:500, LAMP1, Abcam, #ab25245), (1:500, LAMP2, Abcam,
#ab25631), (1:200, ATG5, Thermo Fisher Scientiﬁc, #MA5-38452). For colocalization studies of CTRP5 with endo-lysosomal markers, iRPE were treated
with and without baﬁlomycin (50 nM, Sigma, #B1793-10UG) for 3 h prior to
ﬁxation.
Cells were washed 3x in ICC buffer and secondary antibodies were added at
1:1000 dilution. The following conjugated antibody was used to stain cell borders:
ZO-1 conjugate Alexa Fluor 488 (1:100, Thermo Fisher Scientiﬁc, #339188).
Samples were washed 3x in ICC blocking buffer and mounted onto glass slides
using Fluoromount-G aqueous mounting medium (Southern Biotech,
Birmingham, AL, #0100-01). Images were acquired on a Zeiss Axio Imager M2
inverted ﬂuorescent microscope with Apotome 2 and Zen 2012 software or a Zeiss
800 confocal microscope (Carl Zeiss AG, Oberkochen, DE). Airyscan images were
taken on a Zeiss LSM 880 with Airyscan. All similarly stained samples were imaged
under the same exposure times and adjusted to the same contrast settings before
being exported. For staining of APOE on transwells and cryosectioning of APOEstained iRPE see SI Methods.
Shapemetric analysis. Morphometric analysis of RPE cells was performed using
REShAPE, an open-access cloud computing-based automated image analysis
platform. RPE monolayers were stained for ADIPOR1 or ZO-1 to identify cell

ARTICLE

borders through image segmentation. Analysis was performed on 20x or 40x
images rescaled to 20x. Shapemetric values are displayed as Mean ± SD (See SI
Methods for further details).
VEGF Elisa of cell culture supernatants (R&D systems, DVE00). Prior to the
experiment, selected transwells were washed 1x with DPBS (Gibco, #14190-144)
and media was replaced with fresh 5% serum-containing RPE media. In select
experiments, 1 µM 9-beta-d-arabinofuranoside (ara-A) (Sigma, #A5762-1G), an
AMPK inhibitor, was added to the media. Following media change, the transwell
plate was placed in a CO2 incubator for 6 h. Following incubation, the media from
the apical and basal sides of the transwells were collected on ice. The conditioned
media was centrifuged at 13,200 rpm at 4 °C for 15 min. The supernatant was
transferred to fresh 1.5 mL Eppendorf tubes and frozen on dry ice and stored at
−80 °C. The assay was completed according to the manufacturer’s instructions.
(Note: samples were diluted 20-fold in diluent buffer).
CTRP5 Elisa. iRPE were incubated for 24 h in phenol-red/serum-free RPE media.
Apical and basal media was collected on ice and centrifuged at 13,200 rpm for
15 min at 4 °C. The supernatant was frozen on dry ice and stored at −80 °C.
CTRP5 was measured using a CTRP5 Elisa kit (Aviscera Bioscience, Santa Clara,
CA, Cat#: SK00594-06) per the manufacturer’s instructions. Apical media was
diluted by 16-fold, and basal media was diluted by 8-fold.
Plasma membrane preparation and co-immunoprecipitation (CO-IP). Plasma
membrane preparation of iRPE were prepared using a Plasma Membrane Protein
Extraction Kit (Abcam, #ab65400) following the manufacturer’s recommendations.
In brief, 9 million iRPE cells were collected from transwells on ice. Cell lysates were
prepared by homogenizing cells 30–50 times in premade Homogenization Buffer
Mix in an ice-cold Dounce Homogenizer. Two passes are required to ensure
thorough homogenization. Nuclei were pelleted and discarded, and the supernatant
were further centrifuged at maximal speeds in a microcentrifuge and processed
further to obtain total cell membrane and plasma membrane preps.
Immunoprecipitation was carried out using DynabeadsTM protein G
Immunoprecipitation kit Thermo Fisher,#10007D) per manufacturer’s protocol. In
brief, plasma membrane preps (obtained from 9 million cells) were resuspended in
300 ul of TBST (PBS + 0.5% Triton) and divided into three equal parts. Each part
was probed with anti-AdipoR1 (Santacruz (D-9): #sc-518030, 10ug), PBST, or
matching isotype(IgG), respectively. The latter two samples were control samples
that were used to evaluate the nonspeciﬁc binding of CTRP5. CTRP5 in pull-down
lysates were detected by Western Blot with an anti-CTRP5 antibody (same as
previously reported).
Generation of tagged CTRP5 wildtype and S163R mutant overexpression
system. Coding sequences of the Human CTRP5 wildtype or mutant variant
S163R were cloned into a lentiviral vector, with a V5 or Flag tag included to its Cterminus, respectively. The lenti-construct was designed to express GFP or
mCherry via IRES (Internal ribosome entry site) for monitoring of transduction
efﬁciency and protein expression.
Immunostaining of iRPE overexpressing tagged WT or MUT CTRP5. iRPE
monolayers derived from L-ORD patients were transduced with lentivirus containing tagged WT (V5)and MUT CTRP5(Flag), simultaneously using polybrene
(6 ug/ml) containing media for 3 days. WT CTRP5 contains a V5 tag and MUT
CTRP5 contains a Flag-Tag, both included on the C-terminus of the protein.
Tagged WT CTRP5 was expressed at a constant level (MOI 0.5) and varying tagged
S163R MUT CTRP5 (0.5, 1.5, 3). The cells were ﬁxed in 4% PFA and permeabilized
in ICC blocking buffer (1x PBS, 1% BSA, 0.25% Tween20, 0.25% Triton X-100) for
1 h. The iRPE were incubated with antibodies diluted in ICC blocking buffer at the
following dilutions: V5 (1:250, Abcam, ab27671), Flag (1:200, Thermo Fisher, INC,
#701629).
Native immunogold labeling. Primary antibodies for ADIPOR1 (1:300, Enzo,
#ALX-210-645-C200) and CTRP5 (1:100, Bioss, #bs-11717R) were incubated for
1.5 h at 37 °C in 5% serum-containing RPE media. Cells were subsequently washed
four times in 1x PBS (slowly with a pipette to protect the apical processes). The
immunogold secondary antibodies 6 nm conjugated gold (Jackson Immunoresearch, #705-195-147) and 12 nm conjugated gold (Jackson Immunoresearch,
#711-205-152) were added together each at a dilution of 1:500 for 1.5 h at 37 °C.
Cells were washed four times in 1x PBS and ﬁxed in 2.5% glutaraldehyde + 2.5%
formaldehyde in 0.1 M sodium cacodylate buffered solution (Electron Microscopy
Sciences, #15949) for 72 h and provided to the NEI histopathology core facility for
preparation for TEM imaging.
Phospho-AMPK assay. Phospho-AMPK was measured using the AMPK [pT172]
Elisa Kit (Thermo Fisher Scientiﬁc, #KHO0651) per the manufacturer’s instructions. Cells were either collected at baseline at 37 °C in 5% serum-containing
media, or under serum starvation (5 h) followed by 30 min treatment of 2 mM
AICAR (Sigma, #A9978-5mg) or 100 nM BAM15 (Sigma, #SML1760-5mg). Cells
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pretreated with metformin (3 mM) for 1 week were similarly tested under serum
starvation (5 h) followed by 30 min of 2 mM AICAR.
In experiments to determine the effects of recombinant CTRP5 globular
domain (gCTRP5, Adipogen, #AG-25A-0096-C100) or recombinant CTRP5 full
length (Adipogen, #AG-40A-0142-C050) on pAMPK activation, samples were
serum-starved for 5 h followed by 30 min incubation with recombinant CTRP5
reconstituted in water (gCTRP5: 0.2 µg/mL; full-length CTRP5: 0.2, 2, and 25 µg/
mL). Cells were washed twice with cold 1x PBS prior to adding 200 µL of cell
extraction buffer (Thermo Fisher Scientiﬁc, #FNN0011) and 2 µL Halt Protease
Inhibitor cocktail (100x) (Thermo Fisher Scientiﬁc, #P-2714/78430) per well for
~5 min on ice. Samples were detached by pipetting and vortex three times at 10min intervals. The extract was placed in microcentrifuge tubes and centrifuge at
13,200 rpm for 10 min at 4 °C. The clear lysate (supernatant) was collected and
frozen on dry ice and stored at −80 °C. For the assay, the cell extract samples were
diluted at 1:2.2.
Western blot of iRPE cell lysates. iRPE cells grown on transwells were lysed in
RIPA buffer supplemented with Halt Protease Phosphatase Inhibitor Cocktail
(Thermo Fisher Scientiﬁc, #78440). Total protein was quantiﬁed using BCA analysis (Thermo Fisher Scientiﬁc, #23227) per the manufacturer’s instructions. Buffers for Western blotting: Running Buffer consisted of double deionized water, 10x
Tris/Glycine/SDS (Biorad, #1610732). Transfer buffer consisted of double deionized water, 5x transfer buffer, and 20% ethanol (200 proof). Cell lysates were
separated by denaturing gel electrophoresis and electroblotted onto a PVDF
membrane. Blocking of nonspeciﬁc binding was sufﬁciently obtained with 5% BSA
in PBST. Membranes were incubated 12–18 h at 4 °C with primary antibodies
against PGC1α (Abcam, Cat#: ab54481) and Phospho-PGC1α (S571) (R&D Systems, Cat#: AF6650) and β-Actin (Cell Signaling, #4970 S). After 3x washes in
PBST, the secondary antibodies were added (IR dye −800 and −680) and incubated for 1 h at room temperature. Western blots were imaged using the ChemiDoc
MP Imaging System (Biorad).
Phospholipase A2 assay. Phospholipase A2 enzyme activities was measured using
the EnzChek Phospholipase A2 Assay Kit (Invitrogen, Carlsbad, CA, #E10217) per
the manufacturer’s instructions. Baseline phospholipase A2 (PEDF-R) activity was
measured from healthy and L-ORD-iRPE maintained at 37 °C in 5% serumcontaining RPE media. Phospholipase A2 activity in response to elevated AMPK
was measured after 24 h exposure to 0% serum-containing media in healthy-iRPE.
Samples were collected in a native gel lysis buffer (150 mM NaCl, 1% Triton X-100,
1 M Tris-HCL). Samples were centrifuged at 13,200 rpm for 10 min at 4 °C. The
supernatant was transferred to new tubes and frozen on dry ice and stored at
−80 °C. A total volume of 100 µL was used following the standard assay protocol:
50 µL sample + 50 µL substrate-liposome mix.
Cellular energetics (Seahorse). The Seahorse XFe96 Analyzer (Agilent, Santa
Clara, CA) was used to measure oxygen consumption rate (OCR) and extracellular
acidiﬁcation rate (ECAR). Cells were plated at a density of 1000 cells per well and
allowed to mature to conﬂuency ~7 weeks. All four donors (two healthy, two LORD) were seeded onto the same plate (six replicate wells of each line were used
and the responses across donors (healthy vs L-ORD) were averaged.
LC-MS/MS. We used a Xevo TQ-S mass spectrometer equipped with Acquity I
Class UPLC (Waters Corporation, Milford, MA). CORTECS C18 column (2.7 µm
particle size, 4.6 mm ´ 100 mm i.d.) (Waters Corporation, #186007377) for the
separation of fatty acids and their derivatives. LC conditions are as follow; 45% of
solvent A (H2O + 0.01% acetic acid) and 55% of solvent B (MeOH + 0.01% acetic
acid) with a ﬂow rate of 0.6 mL/min was initially set at 0 min., then gradient was set
for 85% B at 10 min, 98% B at 18 min, 100% B at 20 min, back to 55% B at 30 min.
The capillary voltage was −2.5 kV, desolvation temperature was 600 °C, desolvation gas ﬂow was 1100 L/h, cone gas was 150 L/h, and nebulizer pressure was
7.0 bar with a source temperature of 150 °C. MassLynx ver. 4.1 software (Waters
Corporation) was used for the operation and recording of the data. Data were
expressed as the change in the relative abundance of pro-homeostatic lipid mediators normalized with the internal standards.
Photoreceptor outer segment (POS) phagocytosis assay. The phagocytosis
assay for assessing the functionality of iRPE was performed as mentioned previously (May-Simera et al., 2018; Sharma et al., 2019). Brieﬂy, bovine outer segments were procured commercially (InVision Bioresources, # 98740) and labeled
with pH-sensitive dye pHrodo red dye conjugates (Thermo Fisher Scientiﬁc,
#P36600), as per the manufacturer’s instructions. iRPE cells were fed with pHrodo
labeled photoreceptor outer segment (POS) 10 POS/iRPE cells, for 4 h. Untreated
cells were used as control. After 4 h, cells were washed four times with 1x PBS
(Thermo Fisher Scientiﬁc, #10010-023), and incubated in 0.25% Trypsin-EDTA
(Thermo Fisher Scientiﬁc, #25200056) for 20 min. The Trypsin-EDTA was aspirated off and replaced with RPE maintenance media. Cells were collected in a tube
and centrifuged at 1200 rpm for 5 min. Cell pellets were washed three times with 1x
PBS. After the ﬁnal wash, pellets were resuspended in 600 µL of 0.1% BSA in 1x
PBS; cell suspension was strained through a 40-micron cell strainer (BD
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Biosciences, #14-959-49 A). About 10 µL of DAPI (5 µg/mL) was added to each
tube that contained cell suspension. pHrodo signal (mean ﬂuorescence intensity)
from phagocytosed POS was measured using a MACSQuant Analyzer (Miltenyi
Biotech) for a total of 10,000 counts/treatment. Data were analyzed by FlowJo
software (BD Biosciences). The ratio of fed to unfed samples was plotted.
β-hydroxybutyrate assay. Ringer solution and BSA conjugated Na palmitate were
prepared as described previously24. On the day of the experiment, 2 mM BSApalmitate conjugate was added to Ringer’s solution at 1:10 dilution. Ringer’s
solution containing (BSA-palmitate conjugate) was added to the apical chamber of
iRPE cells grown on 12-well transwell ﬁlters. Ringer’s solution (115 µl) was collected from the apical and basal chamber and analyzed for β-hydroxybutyrate (βHB) at the 3-h time point essentially as described23. The β-HB levels were determined using the β-hydroxybutyrate LiquiColor kit (Stanbio, Boerne, TX, #2440058). In this assay, reagent A was mixed with reagent B at a 6:1 ratio, and 150 µl of
this mixture was added to 100 µl of samples or βHB standards in each well. The
plate was light-protected and incubated at 37 °C for 1 h with gentle shaking before
absorbance at 492 nm was measured.
Statistics and reproducibility. Paired sample (two-sided) t-test analysis was used
to determine if the differences observed between healthy and L-ORD-iRPE were
statistically signiﬁcant (P ≤ 0.05). Statistical analysis was performed in MatLab and
Microsoft Excel. The data were represented as Mean ± Standard Error unless
otherwise noted (e.g., boxplots). Boxplots were performed in R version 3.6.2 or Igor
Pro version 6.37. The 25th, median, and 75th percentiles correspond to the bottom,
middle, and top of each box.
Co-localization analysis was performed using Pearson’s correlation coefﬁcient
calculated by NIS Elements AR software (Nikon). Each experiment presented here
uses averaged data from iRPE derived from four iPSC clones of two unaffected
siblings (healthy-iRPE) and four iPSC clones of two patients (L-ORD-iRPE). For
each ﬁgure, the number of replicates is indicated in the corresponding legend.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All data, reagents, and materials are available upon reasonable request from the
corresponding author (kapil.bharti@nih.gov). Source data for all ﬁgures are provided
in Supplementary Data.
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